Posted in | News | Nanomedicine | Nanoanalysis

FluCide Drug Candidates from NanoViricides Offers Protection from Influenza Virus

NanoViricides declared that it has been invited to be part of the TechConnect World 2011 Conferences and Expo to be held on June 13-16 in Boston, MA to elaborate on its anti-influenza drug development studies.

At this Conference, the President and Chairman of the Company, Dr. Anil R. Diwan, will talk on “Nanoviricides as Anti-Influenza Agents”. The title of the oral presentation scheduled on June 16 is “Bio Nano Materials: Novel bio nano materials and applications”

Till date, the company has conducted many anti-influenza animal efficacy studies and successfully enhanced its FluCide candidates with each efficacy study. Recently, the company has announced that its optimized FluCide drug candidates enabled a 1,000-fold decrease in the levels of fatal influenza virus present in the lungs of animals. During the 21-day study, the company observed that two of its optimized FluCide drug candidates lowered the lung viral load significantly and maintained it throughout.

Treatment using FluCide drug candidates seemed to offer protection from spread of infection, virus expansion, and cycle of infection in the lungs of animals. This explains why animals treated with FluCide during the H1N1 influenza study showed increased survival rates and protection from influenza virus tissue injury.

The company announced that its optimized FluCide drug candidates increased survival considerably and contributed more than 95% decrease in necrosis and lung inflammation. Treatment using FluCide candidates started a day after the occurrence of the initial viral infection.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoViricides, Inc. (2019, February 12). FluCide Drug Candidates from NanoViricides Offers Protection from Influenza Virus. AZoNano. Retrieved on October 10, 2024 from https://www.azonano.com/news.aspx?newsID=22637.

  • MLA

    NanoViricides, Inc. "FluCide Drug Candidates from NanoViricides Offers Protection from Influenza Virus". AZoNano. 10 October 2024. <https://www.azonano.com/news.aspx?newsID=22637>.

  • Chicago

    NanoViricides, Inc. "FluCide Drug Candidates from NanoViricides Offers Protection from Influenza Virus". AZoNano. https://www.azonano.com/news.aspx?newsID=22637. (accessed October 10, 2024).

  • Harvard

    NanoViricides, Inc. 2019. FluCide Drug Candidates from NanoViricides Offers Protection from Influenza Virus. AZoNano, viewed 10 October 2024, https://www.azonano.com/news.aspx?newsID=22637.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.